Tweet
UC-II Improved Knee Joint Symptoms In Knee Arthritis Subjects To A Far Greater Degree When Compared To Placebo And Glucosamine & Chondroitin.
Undenatured Type 2 Collagen 60 Count Amazon
Introduction
Osteoarthritis, which entails the destruction of joint cartilage and remodeling of the adjacent bone, is the most common form of arthritis affecting more than 25 million Americans. Current therapies for OA include various over the counter analgesics, a number of nonsteroidal anti-inflammatory drugs (NSAIDs), intra-articular injections of corticosteroids or hyaluronic acid, plus tramadol and other opioid analgesics to relieve severe pain. While these therapies can alleviate symptoms in the near term, their ultimate impact on the pathophysiologic progression of OA is limited.
Previous studies reported UC-II to be efficacious for the treatment of arthritis. More recently, a statistically significant improvement in knee joint function over placebo was also reported in a clinical study comprising a group of healthy individuals, supplemented with UC-II, and who developed transient knee joint pain upon strenuous exercise. These same individuals also took longer to experience pain after 120 days of supplementation. Based on these observations, the current study was designed to evaluate the efficacy of UC-II in knee OA subjects compared to placebo and to glucosamine and chondroitin, which is a widely available supplement that is used for reducing joint pain.
Study
For their experiment the researchers used three groups of about fifty people who had osteoarthritis in the knee joint. Over a period of six months one group took a placebo every day, a second group took a supplement containing 1500 mg glucosamine and 1200 mg chondroitin, and a third group took 40 mg undenatured type II collagen.
The subjects took half of their capsules in the mornings and the other half in the evenings.
Conclusion
This study found that UC-II, a nutritional ingredient containing undenatured type II collagen, significantly improved knee function in OA subjects by day 180, compared to placebo and to GC, and was well-tolerated. Based on the data presented herein, we believe that additional research is warranted both to confirm and to define these findings more extensively.
________________
References
Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II Arthritis Rheum. 2008;58(1):26–35. doi:10.1002/art.23176.
Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012;64(4):465–74.
National Institute of Health and Care Excellence; NICE clinical guideline 177. Accessed October 19, 2015.
Osteoarthritis, which entails the destruction of joint cartilage and remodeling of the adjacent bone, is the most common form of arthritis affecting more than 25 million Americans. Current therapies for OA include various over the counter analgesics, a number of nonsteroidal anti-inflammatory drugs (NSAIDs), intra-articular injections of corticosteroids or hyaluronic acid, plus tramadol and other opioid analgesics to relieve severe pain. While these therapies can alleviate symptoms in the near term, their ultimate impact on the pathophysiologic progression of OA is limited.
Previous studies reported UC-II to be efficacious for the treatment of arthritis. More recently, a statistically significant improvement in knee joint function over placebo was also reported in a clinical study comprising a group of healthy individuals, supplemented with UC-II, and who developed transient knee joint pain upon strenuous exercise. These same individuals also took longer to experience pain after 120 days of supplementation. Based on these observations, the current study was designed to evaluate the efficacy of UC-II in knee OA subjects compared to placebo and to glucosamine and chondroitin, which is a widely available supplement that is used for reducing joint pain.
Study
For their experiment the researchers used three groups of about fifty people who had osteoarthritis in the knee joint. Over a period of six months one group took a placebo every day, a second group took a supplement containing 1500 mg glucosamine and 1200 mg chondroitin, and a third group took 40 mg undenatured type II collagen.
The subjects took half of their capsules in the mornings and the other half in the evenings.
Conclusion
This study found that UC-II, a nutritional ingredient containing undenatured type II collagen, significantly improved knee function in OA subjects by day 180, compared to placebo and to GC, and was well-tolerated. Based on the data presented herein, we believe that additional research is warranted both to confirm and to define these findings more extensively.
________________
References
Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II Arthritis Rheum. 2008;58(1):26–35. doi:10.1002/art.23176.
Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012;64(4):465–74.
National Institute of Health and Care Excellence; NICE clinical guideline 177. Accessed October 19, 2015.